Moshe Manor compensation by year
Protalix BioTherapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $333,058 | $355,290 | $356,551 | $362,073 |
| Bonus | $0 | $374,000 | $150,000 | — |
| Stock awards | $0 | $0 | — | — |
| Option awards | $250,299 | $103,354 | $106,820 | $39,337 |
| Non-equity incentive | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $98,925 | $105,056 | $104,283 | $214,221 |
| Total | $682,282 | $937,700 | $717,654 | $615,631 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Protalix BioTherapeutics, Inc. DEF 14A filed April 15, 2020, accession 0001104659-20-046926, and prior-year filings.
How this page was built: the Protalix BioTherapeutics, Inc. filed document, accession 0001104659-20-046926. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2020.
Protalix BioTherapeutics’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Moshe Manor · this page | President and Chief Executive Officer | $615,631 |
| Yoseph Shaaltiel | Executive Vice President, Research and Development | $468,321 |
| Einat Almon | Senior Vice President, Product Development | $422,181 |
| Dror Bashan | President and Chief Executive Officer | $391,599 |
| Yaron Naos | Senior Vice President, Operations | $385,739 |
| Yossi Maimon | Vice President, Chief Financial Officer | $306,248 |
| Eyal Rubin | Senior Vice President, Chief Financial Officer | $154,206 |
The full Protalix BioTherapeutics compensation record
free company briefThis page is one person within Protalix BioTherapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Protalix BioTherapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Protalix BioTherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.